Previous 10 | Next 10 |
SAN DIEGO , Sept. 1, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the first subject has been dosed in a Phase 2 trial evaluating etrasimod, an investigational, next-generation, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor mod...
Editors' Note: This is the transcript version of the podcast we published last Wednesday with Rahul Bhushan. Please note that due to time and audio constraints, transcription may not be perfect. We encourage you to listen to the podcast, embedded below, if you need any clarification. We...
Cannabis has long term growth prospects due to the increased decriminalization in various states. Here are two stocks poised to ride the trend: Arena Pharmaceuticals (ARNA) and Innovative Industrial Properties (IIPR). The cannabis industry is comprised of legal cultivators and producers of ...
Arena Pharmaceuticals (NASDAQ: ARNA) has made investors happy campers so far in 2020. Its shares are up more than 40%. The company also reported some good news from its pipeline earlier this year and even enjoyed a boost from positive data for a rival's drug. But when Arena announced its ...
Arena Pharmaceuticals, Inc. (ARNA) Q2 2020 Results Conference Call August 05, 2020 05:00 PM ET Company Participants Laurie Stelzer - CFO Amit Munshi - President & CEO Dr. Chris Cabell - Chief Medical Officer and Head of Research and Development Conference Call Participants...
Image source: The Motley Fool. Arena Pharmaceuticals Inc (NASDAQ: ARNA) Q2 2020 Earnings Call Aug 5, 2020 , 4:30 p.m. ET Operator Continue reading
Arena Pharmaceuticals (NASDAQ: ARNA ) : Q2 GAAP EPS of -$1.61 beats by $0.43 . More news on: Arena Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SAN DIEGO , Aug. 5, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the second quarter ended June 30, 2020 . "Over the quarter, we delivered positive Phase 1 data from the etrasimod controlled-r...
Listen on the go! Subscribe to The Cannabis Investing Podcast on Apple Podcasts , Google Podcasts , Spotify , and Stitcher . By Rena Sherbill Rahul Bhushan co-founded Rize ETF and has a wealth of experience in systematic strategies, indexing and E...
Arena Pharmaceuticals (NASDAQ: ARNA ) is scheduled to announce Q2 earnings results on Wednesday, August 5th, after market close. The consensus EPS Estimate is -$2.00 (-61.3% Y/Y) and the consensus Revenue Estimate is $1.47M (+44.1% Y/Y). Over the last 2 years, ARNA has beaten EPS esti...
News, Short Squeeze, Breakout and More Instantly...
Arena Pharmaceuticals Inc. Company Name:
ARNA Stock Symbol:
NASDAQ Market:
Arena Pharmaceuticals Inc. Website:
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded at a new 52-week high today of $99.95. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares. Arena Pharmaceuticals is a biotechnology company targeting G-protein-couple...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 52-week high of $98.57. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Over the past year, Arena Pharmaceuticals Inc. has traded in a range of $45...